{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:05Z","timestamp":1787313485180,"version":"build-2736575974"},"reference-count":55,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031528","name":"Alfasigma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031528","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,20]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a heterogeneous disease, which current treatment guidelines insufficiently accommodate, as they predominantly emphasise the suppression of disease activity. However, a step towards personalised medicine is preferred to further optimise treatment and requires homogeneous subgroups with similarities in pathophysiological mechanisms and treatment responses. Prior research has already demonstrated notable differences in the pathophysiology of patients with autoantibody-positive and autoantibody-negative RA, as well as differences in treatment responses, which may serve as a strong basis for personalised medicine. Additionally, there is evidence suggesting that an early treatment response is indicative of future courses. Based on these findings, we designed a personalised medicine trial in RA that compares the effectiveness and cost-effectiveness of a tailor-made approach with routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The PeRsonalIsed Medicine in RA (PRIMERA) trial is a multicentre, open-label, randomised controlled trial that includes 300 adult patients with newly diagnosed, DMARD-na\u00efve RA, according to 2010 American College of Rheumatology\/EULAR criteria. Patients are randomised into either routine care or a tailor-made approach. Both management approaches use a treat-to-target strategy, aiming for low disease activity (LDA, Disease Activity Score using 44 joints (DAS) \u22642.4). In routine care, initial treatment consists of methotrexate along with a single intramuscular dose of glucocorticoids (GCs) and treatment can be intensified after 3, 7 and 10 months if LDA is not reached. Conversely, initial treatment in the tailor-made approach depends on the presence of autoantibodies, with patients with autoantibody-positive and autoantibody-negative RA starting with hydroxychloroquine or methotrexate together with a single intramuscular dose of GCs, respectively. Medication intensifications will be allowed at months 1, 3, 4, 7 and 10. Intensifications at months 1 and 4 depend on whether patients have an early sufficient response to GCs and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), respectively. The tailor-made approach is superior to routine care if no more biological DMARDs (bDMARDs) or tsDMARDs are used after 10 months of treatment, while the mean DAS over time is lower. Our primary outcome is the proportional difference in bDMARD or tsDMARD usage after 10 months of treatment between routine care and the tailor-made approach. Secondary outcomes are DAS over time, time to achieve LDA, cost-effectiveness and patient-reported outcome measurements over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been granted by Erasmus MC Medical Ethics Review Committee (MEC-2020-0825). The results will be disseminated through peer-review journals and medical congresses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \" xlink:href=\"NCT16170070\">NCT16170070<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-108887","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:08:36Z","timestamp":1771326516000},"page":"e108887","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct16170070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct16170070","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9487-6098","authenticated-orcid":false,"given":"Hamit Harun","family":"Dag","sequence":"first","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-2182","authenticated-orcid":false,"given":"Agnes E M","family":"Looijen","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E","family":"Vonkeman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The Netherlands"},{"name":"Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Willemze","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy-Anne","family":"Korswagen","sequence":"additional","affiliation":[{"name":"Rheumatology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos C","family":"Padmos","sequence":"additional","affiliation":[{"name":"Rheumatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A","family":"van Gaalen","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[{"name":"Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"van der Kaap","sequence":"additional","affiliation":[{"name":"Rheumatology, Admiraal De Ruyter Hospital, Goes, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien J","family":"Veris-van Dieren","sequence":"additional","affiliation":[{"name":"Rheumatology, Reumazorg ZWN, Roosendaal, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Riyazi","sequence":"additional","affiliation":[{"name":"Rheumatology, Haga Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette H M","family":"van der Helm-van Mil","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"},{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-6222","authenticated-orcid":false,"given":"Pascal H P","family":"de Jong","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026010307023754000_15.12.e108887.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31491-5"},{"key":"2026010307023754000_15.12.e108887.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026010307023754000_15.12.e108887.3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010307023754000_15.12.e108887.4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2103726"},{"key":"2026010307023754000_15.12.e108887.5","doi-asserted-by":"crossref","first-page":"101742","DOI":"10.1016\/j.berh.2022.101742","article-title":"Precision medicine in rheumatoid arthritis","volume":"36","author":"Bhamidipati","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026010307023754000_15.12.e108887.6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","article-title":"Overdiagnosis and overtreatment in rheumatology: a little caution is in order","volume":"77","author":"Landew\u00e9","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026010307023754000_15.12.e108887.7","doi-asserted-by":"crossref","unstructured":"Kubo S , Tanaka Y . Pursuing Precision Medicine in Managing Rheumatoid Arthritis. Int J Rheum Dis 2025;28. doi:10.1111\/1756-185X.70239","DOI":"10.1111\/1756-185X.70239"},{"key":"2026010307023754000_15.12.e108887.8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.rdc.2017.04.008","article-title":"Precision Medicine in Rheumatoid Arthritis","volume":"43","author":"Bluett","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2026010307023754000_15.12.e108887.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033571"},{"key":"2026010307023754000_15.12.e108887.10","doi-asserted-by":"crossref","unstructured":"Sokolove J , Bromberg R , Deane KD , et al . Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7. doi:10.1371\/journal.pone.0035296","DOI":"10.1371\/annotation\/2e462817-ab93-4d78-95a4-1d8b9d172971"},{"key":"2026010307023754000_15.12.e108887.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205428"},{"key":"2026010307023754000_15.12.e108887.12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/rheumatology\/keab631","article-title":"The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes","volume":"61","author":"Luurssen-Masurel","year":"2022","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026010307023754000_15.12.e108887.13","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(24)00234-0","article-title":"Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis","volume":"7","author":"Heutz","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026010307023754000_15.12.e108887.14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/rheumatology\/kead378","article-title":"Synovial and serum B cell signature of autoantibody-negative rheumatoid arthritis vs autoantibody-positive rheumatoid arthritis and psoriatic arthritis","volume":"63","author":"De Stefano","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026010307023754000_15.12.e108887.15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13075-015-0800-5","article-title":"CCR6+ Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis","volume":"17","author":"Paulissen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026010307023754000_15.12.e108887.16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13075-025-03557-0","article-title":"Divergent gene signatures and neutrophil enrichment in lymph nodes of inflammatory arthritis patients","volume":"27","author":"O\u2019Byrne","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026010307023754000_15.12.e108887.17","doi-asserted-by":"crossref","first-page":"103168","DOI":"10.1016\/j.jaut.2024.103168","article-title":"Aberrant B cell receptor signaling in circulating na\u00efve and IgA+ memory B cells from newly-diagnosed autoantibody-positive rheumatoid arthritis patients","volume":"143","author":"Neys","year":"2024","journal-title":"J Autoimmun"},{"key":"2026010307023754000_15.12.e108887.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.012"},{"key":"2026010307023754000_15.12.e108887.19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for Rheumatoid Arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol Ther"},{"key":"2026010307023754000_15.12.e108887.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201117"},{"key":"2026010307023754000_15.12.e108887.21","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1093\/rheumatology\/keab251","article-title":"Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients","volume":"60","author":"Nathalie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026010307023754000_15.12.e108887.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137943"},{"key":"2026010307023754000_15.12.e108887.23","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-025-00509-8","article-title":"Association of matrix metalloproteinase 7 and the alpha-chain of fibrinogen at baseline with response to methotrexate at 3 months in patients with early rheumatoid arthritis","volume":"9","author":"Hambardzumyan","year":"2025","journal-title":"BMC Rheumatol"},{"key":"2026010307023754000_15.12.e108887.24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10067-025-07355-6","article-title":"Evaluating treatment responsiveness in rheumatoid arthritis through predictive metabolomic profiling: A systematic review of studies examining methotrexate, TNF, and IL-6 inhibitors as therapeutic interventions","volume":"44","author":"Musaeva","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026010307023754000_15.12.e108887.25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41927-025-00487-x","article-title":"Transitional and CD21\u2212 PD-1+ B cells are associated with remission in early rheumatoid arthritis","volume":"9","author":"McGrath","year":"2025","journal-title":"BMC Rheumatol"},{"key":"2026010307023754000_15.12.e108887.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202152"},{"key":"2026010307023754000_15.12.e108887.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken204"},{"key":"2026010307023754000_15.12.e108887.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"2026010307023754000_15.12.e108887.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3312-3"},{"key":"2026010307023754000_15.12.e108887.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2026010307023754000_15.12.e108887.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2026010307023754000_15.12.e108887.32","unstructured":"ALEA: tools for clinical trials, version 18.8. Available: https:\/\/www.aleaclinical.eu\/"},{"key":"2026010307023754000_15.12.e108887.33","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"2026010307023754000_15.12.e108887.34","unstructured":"Dijkmans BA , Jacobs JW , Jansen TL , et al . Richtlijnen medicijnen: Methotrexaat. 2011. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-MTX-richtlijn-2009-update-2011.pdf [Accessed 19 May 2019]."},{"key":"2026010307023754000_15.12.e108887.35","unstructured":"Huizinga TWJ , Nurmohamed MT . Standpunt van de Nederlandse Vereniging voor Reumatologie inzake JAK remmers. 2018. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/10\/Jak-remmers-sept-2018.pdf [Accessed 19 May 2019]."},{"key":"2026010307023754000_15.12.e108887.36","unstructured":"Baeten DL , Bijl M , Bijlsma JW , et al . Verantwoord gebruik van biologicals, 2011. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-richtlijn-verantwoord-gebruik-van-biologicals-januari-2011.pdf [Accessed 19 May 2019]."},{"key":"2026010307023754000_15.12.e108887.37","unstructured":"Speyer I . Richtlijnen medicijnen: sulfasalazine. 2002. Available: https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-richtlijn-Sulfasalazine-2002.pdf [Accessed 19 May 2019]."},{"key":"2026010307023754000_15.12.e108887.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"2026010307023754000_15.12.e108887.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046367"},{"key":"2026010307023754000_15.12.e108887.40","unstructured":"iMTA Productivity and Health Research Group . Manual iMTA Medical Cost Questionnaire (iMCQ). Rotterdam: iMTA, Erasmus University Rotterdam, 2018."},{"key":"2026010307023754000_15.12.e108887.41","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2026010307023754000_15.12.e108887.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"2026010307023754000_15.12.e108887.43","first-page":"1574","article-title":"Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff] Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief","volume":"149","author":"Lamers","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2026010307023754000_15.12.e108887.44","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026010307023754000_15.12.e108887.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.059451"},{"key":"2026010307023754000_15.12.e108887.46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JPR.S182287","article-title":"Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity","volume":"12","author":"van Bemmel","year":"2019","journal-title":"J Pain Res"},{"key":"2026010307023754000_15.12.e108887.47","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132488"},{"key":"2026010307023754000_15.12.e108887.48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080182"},{"key":"2026010307023754000_15.12.e108887.49","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"2026010307023754000_15.12.e108887.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00130-9"},{"key":"2026010307023754000_15.12.e108887.51","doi-asserted-by":"crossref","unstructured":"Rodenburg-Vandenbussche S , Pieterse AH , Kroonenberg PM , et al . Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care. PLoS ONE 2015;10. doi:10.1371\/journal.pone.0132158","DOI":"10.1371\/journal.pone.0132158"},{"key":"2026010307023754000_15.12.e108887.52","doi-asserted-by":"publisher","DOI":"10.1191\/026921599668601325"},{"key":"2026010307023754000_15.12.e108887.53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204788"},{"key":"2026010307023754000_15.12.e108887.54","first-page":"1448","article-title":"Declaration of Helsinki (1964)","volume":"313","year":"1996","journal-title":"BMJ"},{"key":"2026010307023754000_15.12.e108887.55","doi-asserted-by":"crossref","unstructured":"Chan A-W , Tetzlaff JM , Gotzsche PC , et al . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346. doi:10.1136\/bmj.e7586","DOI":"10.1136\/bmj.e7586"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-108887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:08:41Z","timestamp":1771326521000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-108887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-108887"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-108887","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}